Let's get to it as this past champ will need your full focus.

SmallCapFirm

Low Float (ATNM) Is A Past Champ And NYSE Profile Requiring Your Immediate Attention This AM

March 25th

SCF Readers,

Let's get to it as this past champ will need your full focus.

Brought to you back in November of 2020, it made an approximate $1.00+ move in under 2 weeks on the heels of some solid company news.

Now, due to several potential catalysts, it looks like it could be run ready again. Here's why...

Some experts say we’re in “the golden age of biotechnology.

Scientific advances are opening up possibilities for the treatment and prevention of diseases that could only have been imagined in the past.

This golden age is also presenting tremendous opportunities.

Biotech stocks can offer huge potential upside based on strong pipelines.

And, one company has a major product pipeline that you need to check out going into Thursday's opening bell:

Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.

Actinium's lead application for their ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities.

With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently.

-----

ATNM Product Pipeline

image
image
image

-----

ATNM's Lead Product Candidate: Iomab-B (Phase 3)

Iomab-B via the monoclonal antibody BC8, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, B cells and stem cells. BC8 is linked to the radioisotope iodine-131 and once attached to its target cells emits energy that travels a relatively long distance, destroying a patient's cancer cells and ablating their bone marrow. By carrying iodine-131 directly to the bone marrow in a targeted manner, Actinium believes Iomab-B will avoid the side effects of radiation on most healthy tissues while effectively killing the patient's cancer and marrow cells.

Iomab-B is currently being studied in the pivotal Phase 3 SIERRA (Study of Iomab-B in Relapsed or Refractory AML) trial, a 150-patient, randomized controlled clinical trial in patients with relapsed or refractory acute myeloid leukemia (AML) who are age 55 and above. The SIERRA trial is being conducted at preeminent transplant centers in the U.S. with the primary endpoint of durable Complete Remission (dCR) at six months and a secondary endpoint of overall survival at one year. Upon approval, Iomab-B is intended to prepare and condition patients for a bone marrow transplant, also referred to as a hematopoietic stem cell transplant, in a potentially safer and more efficacious manner than intensive chemotherapy conditioning that is the current standard of care in bone marrow transplant conditioning. A bone marrow transplant is often considered the only potential cure for patients with certain blood-borne cancers and blood disorders.

In a Phase 2 clinical study in 58 patients with advanced AML or high-risk myelodysplastic syndrome (MDS) age 50 and older, Iomab-B produced complete remissions in 100% of patients and these patients experienced transplant engraftment at day 28. The overall survival rate of the 36 relapsed or refractory AML patients in the proof of concept study was 30% at one year and approximately 20% at two years.

Iomab-B was developed at the Fred Hutchinson Cancer Research Center where it has been studied in several Phase 1 and Phase 2 trials in almost 300 patients in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM) and is currently being studied in several ongoing physician trials. Iomab-B has been granted Orphan Drug Designation for relapsed or refractory AML in patients 55 and above by the U.S. Food and Drug Administration and the European Medicines Agency.

-----

#1 Potential ATNM Catalyst

According to Yahoo Finance, ATNM has a low float.

The website reports this profile to have approximately 13.25Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

With so few shares available for trading, potential catalysts like a positive press release can send shares heading vertical in the short-term.

-----

#2 Potential ATNM Catalyst

There is significant analyst coverage on ATNM.

Roth Capital has given this biotech idea a price target of $180 with HC Wainright providing the most recent target of $65 just about two weeks ago.

Take a look at the multiple targets:

image

Source MarketBeat

Overall, these analysts combined provide a consensus target of $45 according to MarketBeat.

From ATNM's valuation on Wednesday at 1:30PM EST, this provides the profile with potential upside over 425%.

Now, I'm not saying ATNM is going to go soaring to that level today, but you must take note of the potential upside these analysts are providing with their price targets.

-----

#3 Potential ATNM Catalyst

In the past 6 months, ATNM has shown the ability to make major short-term bursts.

In fact, on multiple occasions, ATNM has made multi-dollar moves in the blink of an eye.

Here are a handful of examples:

#1. On 10/2/20, ATNM jumped $3.30+ from a low of $9.00 to a high of $12.36 high on 10/19/20.

#2. On 11/2/20, ATNM popped $3.40+ from a low of $9.71 to a high of $13.18 high on 11/17/20.

#3. On 1/28/21, ATNM climbed $2.50+ from a low of $7.51 to a high of $10.15 high on 2/9/21.

#4. On 3/5/21, ATNM surged $2.40+ from a low of $7.05 to a high of $9.48 high on 3/15/20.

As you can see, all of these moves happened in roughly 2 weeks or less.

Could ATNM's next big breakout be right around the corner?

-----

#4 Potential ATNM Catalyst

Actinium to Highlight Expansion of Targeted Conditioning Portfolio at AACR with Next-Generation Actinium-225-Based CD45 Targeting ARC

- Positive preclinical data support continued development with strong potential in bone marrow transplant, adoptive cell therapy and gene therapy applications

- Potent alpha emitter Actinium-225 targeted to CD45 cells demonstrates positive biodistribution profile and dose-dependent conditioning capabilities

NEW YORK, March 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that preclinical feasibility data supporting an Actinium-225-based CD45-targeted Next-Generation conditioning agent has been accepted for poster presentation at the American Association of Cancer Research (AACR 2021) annual meeting being held virtually April 10th – 15th, 2021. The data to be presented includes initial dose escalation, safety, tolerability, and conditioning experiments of an Ac-225-based CD45 ARC or antibody radiation conjugate. Dosimetry results with this Ac-225-based alpha emitting ARC showed selective accumulation in immune cell target organs such as bone marrow, spleen, and liver with the potential for lower exposure to non-target tissues from longer path length beta emitter radioisotopes like Iodine-131 and Lutetium-177. The data to be presented demonstrate that conditioning with this Ac-225-based CD45-targeting agent result in depletion of peripheral immune cells and hematopoietic progenitor cells, thereby enabling engraftment of donor cells. A dose dependent response was observed with low doses depleting white blood without effecting hematopoietic progenitor cells, representing a lymphodepletive dose that is relevant for adoptive cell therapies such as CAR-T, while higher doses eliminated peripheral immune cells and hematopoietic progenitor cells, which is applicable to ex vivo gene therapies and BMT or bone marrow transplant.

This program further augments Actinium's targeted conditioning portfolio that is led by Iomab-B, an ARC consisting or the radioisotope Iodine-131 and the CD45 targeting antibody apamistamab. In total, apamistamab has been studied in several hundred patients. Iomab-B is currently being studied in the pivotal Phase 3 SIERRA trial for BMT conditioning in patients with active relapsed or refractory acute myeloid leukemia age 55 and above that is expected to complete enrollment in 2021.

Dr. Dale Ludwig, Actinium's Chief Scientific and Technology Officer said, "We are excited to present this data supporting an Ac-225 antibody radiation-conjugate at AACR and to have the opportunity to develop potentially safer and better targeted chemotherapy-free conditioning agents. Recent cases of secondary malignancies potentially tied to toxic chemotherapy regimens highlight the urgent need for improved conditioning to enable the very promising cell and gene therapy strategies to treat diseases such as Sickle Cell Disease and Beta-Thalassemia. As advances in cell and gene therapies address more disease indications and thus a larger overall patient population, our commitment to developing targeted conditioning agents to improve patient access to the these potentially curative therapies and patient outcomes grows stronger. We look forward to further optimizing this construct to enable advancement into the clinic."

[...]

Read the full article here.

-----

#5 Potential ATNM Catalyst

Actinium Showcases Targeted Conditioning Program with 2 Oral Presentations Highlighting Iomab-B and Pivotal Phase 3 SIERRA Trial at 2021 Transplantation & Cellular Therapy Annual Meeting

- TCT conference visibility bolsters strong momentum as SIERRA nears full enrollment following recent positive interim analysis

- Strong results from 75% of patient enrollment highlighted in CME events, oral presentations and investigator interactions at TCT

NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its presence at the 2021 Transplantation & Cellular Therapy (TCT) Annual Meeting, which is being held virtually from February 8th – 12th. The TCT meeting organizes thousands of transplant professionals from over five hundred transplant centers worldwide and is a seminal event for Actinium given its focus on targeted conditioning for bone marrow transplant (BMT), CAR-T and other adoptive cell therapies and gene therapy. At TCT, Actinium's pivotal Phase 3 trial SIERRA trial for Iomab-B was featured in 2 oral presentations, as well as CME event focused on AML and BMT and in investigator interactions led by Actinium's clinical development and medical affairs teams.

Dr. Mark Berger, Actinium's Chief Medical Officer, said, "TCT is the ideal venue to showcase Actinium's Iomab-B and Iomab-ACT targeted conditioning programs given the concentrated audience of thought leaders in these fields that TCT brings together. The timing of TCT is also ideal as it follows shortly after ASH resulting in a data rich period for Actinium that drives investigator interest. This is particularly the case this year as we have built strong momentum in SIERRA following positive data from 75% enrollment featured in 2 oral presentations at ASH and now in 2 oral presentations at this year's TCT, which has driven high levels of investigator and referring physician interactions. We have coupled this with bolstered outreach efforts, which will continue beyond TCT, that have resulted in new site activation despite the advanced stage of SIERRA and robust enrollment rates that give us great confidence in completing SIERRA enrollment rapidly."

[...]

Read the full article here.

-----

Coverage is officially initiated on ATNM. When you have a second later on, do this:

image

Before Thursday's opening bell, get ATNM on your radar.

Sincerely,

Axel Adams

Editor, SCF


Source

Company Website


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

Disclosure: Make sure to always do your own research and due diligence on any day and swing trade profile I bring to your attention. I am not a license d finan.cial advise r. All potential percentage gains are based on from the low to the high of day. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure StockWireNews (stockwirenews . com) is owned by StockNewsWire LLC, a limited liability company. An owner of StockNewsWire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com (“SCF”), an interest in the limited liability company that owns and operates fierceinvestor . com (“FI”), an interest in the limited liability company that owns and operates stockstreetwire . com (SSW), and an interest in the limited liability company that owns and operates nasdaq wire news . com (NWN) . From time to time, StockWireNews, SCF, FI, SSW, and/or NWN will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SmallCapFirm and StockNewsWire, LLC, SmallCapFirm was hired for a one day period on 1/13/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid five thousand USD via bank wire transfer. We own zero shares of (ATNM). An owner of StockNewsWire, LLC owns an interest in SmallCapFirm. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a one day period on 1/13/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We were paid twenty thousand USD via bank wire transfer. We own zero shares of (ATNM). An owner of StockNewsWire, LLC owns an interest in SmallCapFirm. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a one day period on 1/28/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid ten thousand USD via bank wire transfer. We own zero shares of (ATNM). An owner of StockNewsWire, LLC owns an interest in SmallCapFirm. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a one day period on 3/5/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). Pursuant to an agreement between SmallCapFirm and StockNewsWire, LLC, SmallCapFirm was hired for a period beginning on 10/21/20 and ending on 10/22/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid five thousand USD via bank wire transfer. We own zero shares of (ATNM). An owner of StockNewsWire, LLC owns an interest in SmallCapFirm. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews was hired for a period beginning on 10/21/20 and ending on 10/22/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). Pursuant to an agreement between SmallCapFirm and StockWireNews LLC, SmallCapFirm has been hired for a period beginning on 11/5/20 and ending on 11/6/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid five thousand USD via bank wire transfer. We own zero shares of (ATNM). An owner of StockNewsWire, LLC owns an interest in SmallCapFirm. Pursuant to an agreement between StockWireNews LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 11/5/20 and ending on 11/6/20 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid thirty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). Pursuant to an agreement between SmallCapFirm and StockNewsWire, LLC, SmallCapFirm has been hired for a period beginning on 3/24/21 and ending on 3/26/21 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid five thousand USD via bank wire transfer. We own zero shares of (ATNM). To date, we have been compensated a total of twenty thousand USD via bank wire transfer to disseminate information about (ATNM). An owner of StockNewsWire, LLC owns an interest in SmallCapFirm. Pursuant to an agreement between StockNewsWire LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 3/24/21 and ending on 3/26/21 to publicly disseminate information about (ATNM) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (ATNM). To date, we have been compensated a total of one hundred and thirty thousand USD via bank wire transfer to disseminate information about (ATNM).